These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37923025)

  • 1. Use of the TD50 99 % CI for single dose rodent carcinogenicity studies.
    Thomas R; Oliveira AAF; Ponting DJ; Thresher A
    Toxicol Lett; 2023 Dec; 390():1-4. PubMed ID: 37923025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilisation of parametric methods to improve percentile-based estimates for the carcinogenic potency of nitrosamines.
    Thomas R; Thresher A; Ponting DJ
    Regul Toxicol Pharmacol; 2021 Apr; 121():104875. PubMed ID: 33556416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Summary of carcinogenic potency and positivity for 492 rodent carcinogens in the carcinogenic potency database.
    Gold LS; Slone TH; Bernstein L
    Environ Health Perspect; 1989 Feb; 79():259-72. PubMed ID: 2707207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved in silico prediction of carcinogenic potency (TD50) and the risk specific dose (RSD) adjusted Threshold of Toxicological Concern (TTC) for genotoxic chemicals and pharmaceutical impurities.
    Contrera JF
    Regul Toxicol Pharmacol; 2011 Feb; 59(1):133-41. PubMed ID: 20933038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity profiles of carcinogenicity data: application in hazard identification and risk assessment.
    Jackson MA; Stack HF; Waters MD
    Mutat Res; 1997 Nov; 394(1-3):113-24. PubMed ID: 9434850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of carcinogenicity from two versus four sex-species groups in the carcinogenic potency database.
    Gold LS; Slone TH
    J Toxicol Environ Health; 1993 May; 39(1):143-57. PubMed ID: 8492327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative factors in chemical carcinogenesis: variation in carcinogenic potency.
    Krewski D; Szyszkowicz M; Rosenkranz H
    Regul Toxicol Pharmacol; 1990 Aug; 12(1):13-29. PubMed ID: 2217915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data.
    Thresher A; Foster R; Ponting DJ; Stalford SA; Tennant RE; Thomas R
    Regul Toxicol Pharmacol; 2020 Oct; 116():104749. PubMed ID: 32777431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Collaborative Initiative to Establish Genomic Biomarkers for Assessing Tumorigenic Potential to Reduce Reliance on Conventional Rodent Carcinogenicity Studies.
    Corton JC; Mitchell CA; Auerbach S; Bushel P; Ellinger-Ziegelbauer H; Escobar PA; Froetschl R; Harrill AH; Johnson K; Klaunig JE; Pandiri AR; Podtelezhnikov AA; Rager JE; Tanis KQ; van der Laan JW; Vespa A; Yauk CL; Pettit SD; Sistare FD
    Toxicol Sci; 2022 Jun; 188(1):4-16. PubMed ID: 35404422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Important Points at Interpretation ofNongenotoxic-Carcinogenicity Induced by Pesticidesin Rodent Bioassays].
    Satoh H; Machino S; Fujii T; Yoshida M; Asano S; Yokoyama Y; Miyajima K
    Shokuhin Eiseigaku Zasshi; 2022; 63(1):34-42. PubMed ID: 35264520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computer-aided rodent carcinogenicity prediction.
    Lagunin AA; Dearden JC; Filimonov DA; Poroikov VV
    Mutat Res; 2005 Oct; 586(2):138-46. PubMed ID: 16112600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative correlation of carcinogenic potency with four different classes of short-term test data.
    Travis CC; Wang LA; Waehner MJ
    Mutagenesis; 1991 Sep; 6(5):353-60. PubMed ID: 1795638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Supplement to the Carcinogenic Potency Database (CPDB): results of animal bioassays published in the general literature in 1993 to 1994 and by the National Toxicology Program in 1995 to 1996.
    Gold LS; Manley NB; Slone TH; Rohrbach L
    Environ Health Perspect; 1999 Aug; 107 Suppl 4(Suppl 4):527-600. PubMed ID: 10421768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Carcinogenic Potency Database: analyses of 4000 chronic animal cancer experiments published in the general literature and by the U.S. National Cancer Institute/National Toxicology Program.
    Gold LS; Slone TH; Manley NB; Garfinkel GB; Hudes ES; Rohrbach L; Ames BN
    Environ Health Perspect; 1991 Dec; 96():11-5. PubMed ID: 1820251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative prediction of human cancer risk from rodent carcinogenic potencies: a closer look at the epidemiological evidence for some chemicals not definitively carcinogenic in humans.
    Goodman G; Wilson R
    Regul Toxicol Pharmacol; 1991 Oct; 14(2):118-46. PubMed ID: 1792349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uncertainty in cancer risk estimates.
    Gaylor DW; Chen JJ; Sheehan DM
    Risk Anal; 1993 Apr; 13(2):149-54. PubMed ID: 8502788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
    Gaylor DW
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the correlation coefficient between the TD50 and the MTD.
    Razzaghi M; Gaylor DW
    Risk Anal; 1996 Feb; 16(1):107-13. PubMed ID: 8868225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of TD
    Thresher A; Gosling JP; Williams R
    Toxicol Res (Camb); 2019 Sep; 8(5):696-703. PubMed ID: 31588346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the dependence of the TD50 on maximum tolerated dose for mutagens and nonmutagens.
    Goodman G; Wilson R
    Risk Anal; 1992 Dec; 12(4):525-33. PubMed ID: 1480798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.